
Opinion|Videos|March 4, 2025
Treatment Options in mCRC: A Clinical Overview
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
- Fruquintinib
- Regorafenib
- Trifluridine + tipiracil ± bevacizumab
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
RSV Vaccination Effective in Older Adults, but Protection Declines Over Time
3
Older Adults Drive Hospitalizations, Costs in the US 2024-2025 Influenza Season
4
Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications
5













































